High-grade serous ovarian carcinomas are notorious for developing resistance to PARP inhibitors at progression15 and this appears to frequently arise from either activating fusions of ABCB1 or functionally revertant variants arising in BRCA and Fanconi anemia genes. The gene discussed is ABCB1; the disease is ovarian serous carcinoma.